Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer
暂无分享,去创建一个
Y. Nakatani | K. Nakagawa | H. Kawakami | Yasutoshi Takashima | S. Arima | Y. Otsuka | A. Ito | S. Yamamoto | Masashi Ichikawa | Akiko Mashiko | Akihiko Ito
[1] S. Halford,et al. Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2. , 2018 .
[2] S. Sallan,et al. A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry. , 2018 .
[3] P. Ott,et al. Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. , 2018 .
[4] T. Yoshikawa,et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[5] Kaoru Tanaka,et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer , 2017, JAMA oncology.
[6] M. Perazella,et al. Adverse kidney effects of epidermal growth factor receptor inhibitors , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] J. Lutzky,et al. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor , 2017, Journal of Immunotherapy for Cancer.
[8] K. Jhaveri,et al. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review , 2017, American Journal of Nephrology.
[9] C. Robert,et al. Renal effects of immune checkpoint inhibitors , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] J. Mazières,et al. Acute interstitial nephritis related to immune checkpoint inhibitors , 2016, British Journal of Cancer.
[11] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[12] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[13] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Yuzhang Wu,et al. Expression of B7-H1 in Inflammatory Renal Tubular Epithelial Cells , 2005, Nephron Experimental Nephrology.
[15] L. Glimcher,et al. MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. , 1990, Kidney international.